Cilostazol attenuates diabetic motor neuropathy

• Main Authors: Yu-Ming Wu, 吳育銘
• Other Authors: Kuang-I Cheng
• Format: Others
• Language: zh-TW
• Published: 2017
• Online Access: http://ndltd.ncl.edu.tw/handle/57075397857692716273

碩士 === 高雄醫學大學 === 醫學系生物化學科碩士班 === 105 === Background: Diabetic neuropathy is the most common and intractable complication and pose great therapeutic challenges. Researches regarding diabetic neuropathy is often ascribed to sensory damage of peripheral nerves, however, information on diabetic neuropathic related to the motor and central nervous system are limited and rarely assess in animal models. Aim:We measured physiological, biochemical, motor behavioural changes, motor neurons and Schwann cells alteration in diabetic rats. Additionally, cilostazol, which inhibits type III phosphodiesterase (PDE), is an antiplatelet agent with a vasodilating action are used to assess the efficacy in the treatment of diabetic neuropathy. Methods: Sprague-Dawlay (SD) rats were divided into three groups: group normal (N); group diabetics (DM) [60 mg/kg streptozotocin (STZ) administration via the right femoral vein] and group diabetes treat with cilostazol (DM+cilo) [STZ-induced DM rats with Cilostazol (100mg/kg) orally administered 2 weeks after STZ- induced diabetes and given daily for six weeks]. Physiological and biochemical changes including intake/output (I/O), weight, plasma glucose, triglyceride and total cholesterol were measured. Motor behavioural tests including running speed, runnung distance, foot pressure and sciatic function index were evaluated. Number of motor neuron cells in L5 spinal ventral horn, proliferation of schwann cell and myelinationin sciatic nerve were assessed Results: Diabetes caused hyperglycemia, weight loss, dyslipidemia and high intake/output (I/O). Cilostazol administration significantly decreased I/O, plasma triglyceride and total cholesterol, but difference on plasma glucose and body weight between group DM and DM+cilo was not found. Diabetes also leads to motor function disorder such as lower running speed, high foot pressure and hindpaw contraction. In addition, diabetes contribute to decrease motor neurons in L5 spinal ventral horn, Schwann cells and myelination in sciatic nerve and ventral root. Cilostazol administration ameliorate motor behavior disorder, alleviate damage of Schwann cells and nerve myelination in ventral root and sciatic nerve, but not significantly effect on motor neuron in L5 spinal ventral horn. Conclusion: Cilostazol administration was effective on attenuation of diabetic motor function disorder and motor neuropathy in peripheral nervous system.